Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPH - Cytoclonal Pharmaceutics -- Ignore unavailable to you. Want to Upgrade?

To: SPEEDRACER who wrote (221)	7/2/1998 10:35:00 AM
From: Doug Coughlan	Read Replies (1) \| Respond to of 428

DALLAS, July 2 /PRNewswire/ -- Cytoclonal Pharmaceutics Inc., (Nasdaq: CYPH, CYPHW, CYPHZ) announced today that it received a United States Patent (No. 5,773,579) for a lung cancer marker developed by company scientists. The protein (LCG protein) is localized on the surface of certain lung cancer cells based on Human Clinical Trials. The protein is being developed as a diagnostic test for a type of lung cancer (non-small) which makes up about 65% of all lung cancer which is the second most common form of cancer. The LCG protein is also being developed as a target for delivering paclitaxel (active ingredient in Taxol(R)) to lung cancer tissue so as to reduce toxicity to normal tissue. The company has been developing a microbial fermentation process for Paclitaxel production and recently entered into agreements with Bristol-Myers Squibb. The LCG protein is encoded by the LCG gene for which the company received a Patent No: 5,589,579 in December, 1996. Dr. Arthur P. Bollon, Chairman and CEO, indicated that for commercial development of the lung cancer diagnostics and drug delivery it is critical to have patents for both the gene and protein which has been achieved with this new patent. SOURCE Cytoclonal Pharmaceutics Inc.